Turchini, Laura
 Distribuzione geografica
Continente #
NA - Nord America 217
EU - Europa 179
AS - Asia 39
AF - Africa 1
Totale 436
Nazione #
US - Stati Uniti d'America 216
IT - Italia 62
SE - Svezia 53
IE - Irlanda 18
FR - Francia 17
CN - Cina 16
SG - Singapore 14
DE - Germania 7
KR - Corea 6
GB - Regno Unito 5
FI - Finlandia 3
NL - Olanda 3
PT - Portogallo 3
ES - Italia 2
IN - India 2
AT - Austria 1
CA - Canada 1
HR - Croazia 1
JP - Giappone 1
MK - Macedonia 1
NG - Nigeria 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
Totale 436
Città #
Chandler 63
Ashburn 34
Rome 21
New York 18
Dublin 16
Marseille 14
Singapore 10
Boardman 9
Boston 7
Milan 7
Princeton 7
Seoul 6
Beijing 4
Bergamo 3
Chelsea 3
Lisbon 3
Munich 3
Seattle 3
Washington 3
Ancona 2
Arzachena 2
Atlanta 2
Bremen 2
Cagliari 2
Cattolica 2
Duiven 2
Helsinki 2
Houston 2
Los Angeles 2
Monza 2
Oristano 2
Paris 2
Pune 2
Rancho Cucamonga 2
Spring Arbor 2
Amsterdam 1
Brescia 1
Busto Arsizio 1
Claremont 1
Dortmund 1
Florence 1
Frankfurt am Main 1
Gdansk 1
Girona 1
Harlow 1
Hirakata 1
Hounslow 1
Iesi 1
Lagos 1
Lappeenranta 1
Massa 1
Mondolfo 1
Montreal 1
Pamplona 1
Sacramento 1
San Diego 1
Santa Clara 1
Trieste 1
Vienna 1
Zagreb 1
Totale 291
Nome #
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 59
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 55
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 48
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 45
Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial 43
The gut–brain axis in irritable bowel syndrome and inflammatory bowel disease 43
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 42
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 32
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 31
Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19 19
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 17
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 9
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 7
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 3
Totale 453
Categoria #
all - tutte 2.928
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.928


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202241 0 0 0 0 0 0 0 0 0 9 19 13
2022/2023213 32 25 11 20 21 18 23 11 19 4 8 21
2023/2024195 3 34 16 9 7 33 15 15 10 15 18 20
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 453